Clinical Trials Logo

Filter by:
NCT ID: NCT00000236 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine Pharmacology Related to Addiction Treatment - 18

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

NCT ID: NCT00000239 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine Pharmacology Related to Addiction Treatment - 21

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.

NCT ID: NCT00000267 Completed - Clinical trials for Cocaine-Related Disorders

Risperidone Treatment in Dually-Diagnosed Individuals - 2

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

NCT ID: NCT00000302 Completed - Heroin Dependence Clinical Trials

Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare liquid and tablet buprenorphine formulations.

NCT ID: NCT00000312 Completed - Clinical trials for Cocaine-Related Disorders

Alterations in Serotonergic Functions in Cocaine Addicts - 1

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate alterations in the serotonergic system in cocaine addicts and attempt to dissociate changes secondary to cocaine use from those associated with premorbid characteristics.

NCT ID: NCT00000325 Completed - Clinical trials for Cocaine-Related Disorders

Psychostimulant Abuse - Novel Treatment Approaches - 1

Start date: n/a
Phase: Phase 1
Study type: Interventional

To determine if acute assessments of profasi and factrel affect plasma cocaine levels and cocaine-induced behavioral changes in men.

NCT ID: NCT00000344 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.

NCT ID: NCT00000358 Completed - Clinical trials for Substance-Related Disorders

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

NCT ID: NCT00000363 Completed - Otitis Media Clinical Trials

Acute Otitis Media: Adjuvant Therapy to Improve Outcome

Start date: n/a
Phase: Phase 3
Study type: Interventional

Acute otitis media is one of the most common diseases of childhood and is one of the major causes of hearing loss in children. Despite the availability of effective antibiotic therapy for otitis media, treatment failures, persistent effusions, and recurrences are common. This Phase III outpatient study aims to test whether adjuvant therapy (an antihistamine or a corticosteroid), in addition to antibiotic therapy, improves the acute and long-term outcomes of patients with acute otitis media. This study is targeted to recruiting 200 infants (age less than one year); patient (and parent) participation is estimated to continue for one year after enrollment.

NCT ID: NCT00000390 Completed - Depression Clinical Trials

Antidepressant Treatment of AIDS Related Depression.

Start date: n/a
Phase: Phase 2
Study type: Interventional

To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.